U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
Jul 14, 2022
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md., July 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the N